LRRK2 function on actin and microtubule dynamics in Parkinson disease

Communicative and Integrative Biology

Volumn 3, Issue 5, 2010, Pages 396-400

  Parisiadou, Loukia ^a   Cai, Huaibin ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

ERM; Filamentous actin; G2019S; Golgi apparatus; LRRK2; Microtubule; Neuronal morphogenesis; Parkinson disease; Phosphorylation; Tubulin

Indexed keywords

EID: 77958093993     PISSN: None     EISSN: 19420889     Source Type: Journal    
DOI: 10.4161/cib.3.5.12286     Document Type: Article

References (56)

1. Witte H, Bradke F. The role of the cytoskeleton during neuronal polarization. Curr Opin Neurobiol 2008; 18:479-87.
2. Bradke F, Dotti CG. Establishment of neuronal polarity: lessons from cultured hippocampal neurons. Curr Opin Neurobiol 2000; 10:574-81.
3. McMurray CT. Neurodegeneration: diseases of the cytoskeleton? Cell Death Differ 2000; 7:861-5.
4. Cairns NJ, Lee VM, Trojanowski JQ. The cytoskeleton in neurodegenerative diseases. J Pathol 2004; 204:438-49.
5. Galloway PG, Mulvihill P, Perry G. Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am J Pathol 1992; 140:809-22.
6. Nimmrich V, Ebert U. Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid. Rev Neurosci 2009; 20:1-12.
7. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65:66-79.
8. Kirschner M, Mitchison T. Beyond self-assembly: from microtubules to morphogenesis. Cell 1986; 45:329-42.
9. Inoue S, Salmon ED. Force generation by microtubule assembly/disassembly in mitosis and related movements. Mol Biol Cell 1995; 6:1619-40.
10. Burbank KS, Mitchison TJ. Microtubule dynamic instability. Curr Biol 2006; 16:516-7.
11. Conde C, Caceres A. Microtubule assembly, organization and dynamics in axons and dendrites. Nature Rev Neurosci 2009; 10:319-32.
12. Feng J. Microtubule: a common target for parkin and Parkinson's disease toxins. Neuroscientist 2006; 12:469-76.
13. Ren Y, Liu W, Jiang H, Jiang Q, Feng J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J Biol Chem 2005; 280:34105-12.
14. Ren Y, Jiang H, Yang F, Nakaso K, Feng J. Parkin protects dopaminergic neurons against microtubuledepolymerizing toxins by attenuating microtubuleassociated protein kinase activation. J Biol Chem 2009; 284:4009-17.
15. Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, et al. Tubulin seeds alpha-synuclein fibril formation. J Biol Chem 2002; 277:2112-7.
16. Yang F, Jiang Q, Zhao J, Ren Y, Sutton MD, Feng J. Parkin stabilizes microtubules through strong binding mediated by three independent domains. J Biol Chem 2005; 280:17154-62.
17. Lee HJ, Khoshaghideh F, Lee S, Lee SJ. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. Eur J Neurosci 2006; 24:3153-62.
18. Sousa VL, Bellani S, Giannandrea M, Yousuf M, Valtorta F, Meldolesi J, et al. {alpha}-synuclein and its A30P mutant affect actin cytoskeletal structure and dynamics. Mol Biol Cell 2009; 20:3725-39.
19. Esposito A, Dohm CP, Kermer P, Bahr M, Wouters FS. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Neurobiol Disease 2007; 26:521-31.
20. Kim KH, Son JH. PINK1 gene knockdown leads to increased binding of parkin with actin filament. Neurosci Lett 2010; 468:272-6.
21. Lim MK, Kawamura T, Ohsawa Y, Ohtsubo M, Asakawa S, Takayanagi A, et al. Parkin interacts with LIM Kinase 1 and reduces its cofilin-phosphorylation activity via ubiquitination. Exp Cell Res 2007; 313:2858-74.
22. Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, Long CX, et al. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 2009; 29:13971-80.
23. Bradke F, Dotti CG. The role of local actin instability in axon formation. Science 1999; 283:1931-4.
24. Geraldo S, Gordon-Weeks PR. Cytoskeletal dynamics in growth-cone steering. J Cell Sci 2009; 122:3595-604.
25. Zhou Y, Gu G, Goodlett DR, Zhang T, Pan C, Montine TJ, et al. Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem 2004; 279:39155-64.
26. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 2009; 11:22.
27. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Annals Neurol 2006; 60:389-98.
28. Webber PJ, West AB. LRRK2 in Parkinson's disease: function in cells and neurodegeneration. FEBS J 2009; 276:6436-44.
29. Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, Chen SG. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 2007; 313:3658-70.
30. Santpere G, Ferrer I. LRRK2 and neurodegeneration. Acta Neuropathol 2009; 117:227-46.
31. Han BS, Iacovitti L, Katano T, Hattori N, Seol W, Kim KS. Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra. Neuroscience Lett 2008; 442:190-4.
32. Hatano T, Kubo S, Imai S, Maeda M, Ishikawa K, Mizuno Y, et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Human Mol Genet 2007; 16:678-90.
33. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Annals Neurol 2006; 60:557-69.
34. Biskup S, West AB. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta 2009; 1792:625-33.
35. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature Rev Neurosci 2006; 9:1231-3.
36. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005; 102:16842-7.
37. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006; 52:587-93.
38. Mangeat P, Roy C, Martin M. ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol 1999; 9:187-92.
39. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002; 3:586-99.
40. Turunen O, Wahlstrom T, Vaheri A. Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J Cell Biol 1994; 126:1445-53.
41. Paglini G, Kunda P, Quiroga S, Kosik K, Caceres A. Suppression of radixin and moesin alters growth cone morphology, motility and process formation in primary cultured neurons. J Cell Biol 1998; 143:443-55.
42. Tsukita S, Oishi K, Sato N, Sagara J, Kawai A, Tsukita S. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 1994; 126:391-401.
43. Tamma G, Klussmann E, Procino G, Svelto M, Rosenthal W, Valenti G. cAMP-induced AQP2 translocation is associated with RhoA inhibition through RhoA phosphorylation and interaction with RhoGDI. J Cell Sci 2003; 116:1519-25.
44. Haas MA, Vickers JC, Dickson TC. Rho kinase activates ezrin-radixin-moesin (ERM) proteins and mediates their function in cortical neuron growth, morphology and motility in vitro. J Neurosci Res 2007; 85:34-46.
45. Mutez E, Larvor L, Lepretre F, Mouroux V, Hamalek D, Kerckaert JP, et al. Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. Neurobiol Aging 2010; In press.
46. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 2006; 15:223-32.
47. Gandhi PN, Wang X, Zhu X, Chen SG, Wilson-Delfosse AL. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res 2008; 86:1711-20.
48. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson'sdisease-related mutant alpha-synuclein. Neuron 2009; 64:807-27.
49. MacRae TH. Tubulin post-translational modifications-enzymes and their mechanisms of action. Eur J Biochem 1997; 244:265-78.
50. Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration? J Neurochem 2009; 110:1514-22.
51. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 1975; 72:1858-62.
52. Cole NB, Lippincott-Schwartz J. Organization of organelles and membrane traffic by microtubules. Curr Opinion Cell Biol 1995; 7:55-64.
53. Lane J, Allan V. Microtubule-based membrane movement. Biochim Biophys Acta 1998; 1376:27-55.
54. Thyberg J, Moskalewski S. Microtubules and the organization of the Golgi complex. Exp Cell Res 1985; 159:1-16.
55. Thyberg J, Moskalewski S. Role of microtubules in the organization of the Golgi complex. Exp Cell Res 1999; 246:263-79.
56. Wehland J, Henkart M, Klausner R, Sandoval IV. Role of microtubules in the distribution of the Golgi apparatus: effect of taxol and microinjected anti-alpha-tubulin antibodies. Proc Natl Acad Sci USA 1983; 80:4286-90.